Wall Street brokerages expect that Heska Co. (NASDAQ:HSKA) will report $0.49 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Heska’s earnings, with estimates ranging from $0.44 to $0.53. Heska posted earnings of $0.44 per share in the same quarter last year, which would indicate a positive year over year growth rate of 11.4%. The business is scheduled to announce its next earnings results on Monday, July 30th.
According to Zacks, analysts expect that Heska will report full year earnings of $1.93 per share for the current year, with EPS estimates ranging from $1.84 to $2.00. For the next financial year, analysts expect that the firm will post earnings of $2.18 per share, with EPS estimates ranging from $2.12 to $2.23. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Heska.
Heska (NASDAQ:HSKA) last released its earnings results on Friday, May 4th. The medical research company reported $0.28 EPS for the quarter, missing the Zacks’ consensus estimate of $0.40 by ($0.12). The firm had revenue of $32.77 million during the quarter, compared to analysts’ expectations of $31.65 million. Heska had a net margin of 5.57% and a return on equity of 13.30%.
HSKA has been the subject of a number of research analyst reports. B. Riley set a $93.00 target price on Heska and gave the company a “hold” rating in a research note on Monday, February 26th. Sidoti upgraded Heska from a “neutral” rating to a “buy” rating and set a $94.00 target price for the company in a research note on Monday, February 5th. BidaskClub upgraded Heska from a “hold” rating to a “buy” rating in a research note on Saturday, April 21st. Benchmark raised their target price on Heska from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, May 7th. Finally, ValuEngine upgraded Heska from a “sell” rating to a “hold” rating in a research note on Friday, May 4th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $100.75.
A number of large investors have recently made changes to their positions in the business. BlackRock Inc. raised its stake in shares of Heska by 5.5% in the first quarter. BlackRock Inc. now owns 928,761 shares of the medical research company’s stock worth $73,437,000 after purchasing an additional 48,347 shares during the last quarter. Park West Asset Management LLC raised its stake in shares of Heska by 293.3% in the fourth quarter. Park West Asset Management LLC now owns 347,646 shares of the medical research company’s stock worth $27,885,000 after purchasing an additional 259,256 shares during the last quarter. TimesSquare Capital Management LLC purchased a new position in shares of Heska in the fourth quarter worth $23,831,000. Bank of New York Mellon Corp raised its stake in shares of Heska by 110.1% in the fourth quarter. Bank of New York Mellon Corp now owns 210,669 shares of the medical research company’s stock worth $16,897,000 after purchasing an additional 110,391 shares during the last quarter. Finally, Redmile Group LLC purchased a new position in shares of Heska in the fourth quarter worth $15,753,000. Institutional investors and hedge funds own 85.81% of the company’s stock.
Shares of Heska traded up $0.40, reaching $92.89, on Friday, according to MarketBeat.com. The stock had a trading volume of 121,077 shares, compared to its average volume of 74,658. The stock has a market cap of $686.75 million, a PE ratio of 44.87 and a beta of 0.68. Heska has a 12-month low of $91.97 and a 12-month high of $93.04.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Get a free copy of the Zacks research report on Heska (HSKA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.